A novel phosphonate for the repair of critical size bone defects

Journal of Tissue Engineering and Regenerative Medicine

Volumn 6, Issue 10, 2012, Pages 833-840

  Bassi, A K ^a   Gough, J E ^a   Downes, S ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Biodegradable polymers; Bone tissue engineering; Critical size defects; Micro CT; Organ culture; Osteoporosis

Indexed keywords

BIODEGRADABLE POLYMERS; BONE; COLLAGEN; DEFECTS; DEPOSITION; ENERGY DISPERSIVE SPECTROSCOPY; HYDROXYAPATITE; MAMMALS; SCAFFOLDS (BIOLOGY); SCANNING ELECTRON MICROSCOPY;

BONE DEFECT; BONE TISSUE ENGINEERING; CRITICAL SIZE; CRITICAL SIZE DEFECT; DEFECT SITES; MICRO CT; ORGAN CULTURE; PHOSPHONATES; PHOSPHONIC; POLYVINYLS;

COMPUTERIZED TOMOGRAPHY;

EID: 84868195679     PISSN: 19326254     EISSN: 19327005     Source Type: Journal    
DOI: 10.1002/term.491     Document Type: Article

References (30)

1. Burchardt H. 1983; The Biology of bone graft repair. Clin Orthop Relat Res 174: 28-42.
2. Chesnut III CH, Skag A, Christiansen C, et al. 2004; Effects of oral ibandronate administered daily or intermittently on fracture risk in post menopausal osteoporosis. J Bone Miner Res 19: 1241-1249.
3. Coxon FP, Helfrich MH, Larijani B, et al. 2001; Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages. J Biol Chem 276: 48213-48222.
4. Coxon FP, Thompson K, Rogers MJ. 2006; Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol 6: 307-312.
5. Deutche Banc and Alex Brown. 2001; Estimates and company information.
6. EU policy Report. 2005; Osteoporosis in Europe: indicators of Progress. International Osteoporosis Foundation.
7. Finkemeier CG. 2002; Bone-Grafting and Bone-Graft Substitutes. J Bone Joint Surg Am 84: 454-464.
8. Fisher JE, Rogers MJ, Halasy JM, et al. 1999; Mechanism of action of alendronate: geranylgeraniol, an intermediate of the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption and kinase activation in vitro. Proc Natl Acad Sci 96: 133-138.
9. Gullberg B, Johnell O, Kanis JA. 1997; World-wide projections for hip fracture. Osteoporos Int 7: 407-413.
10. Hench LL, Polak JM, 2002; Third-generation biomedical materials. Science 295: 1014-1017.
11. Hutmacher DW. 2000; Scaffolds in tissue engineering bone and cartilage. Biomaterials 21: 2529-2543.
12. Itokawa H, Hiraide T, Moriya M, et al. 2007; A 12-month in vivo study on the response of bone to a hydroxyapatite-polymethylmethacrylate cranioplasty composite. Biomaterials 28: 4922-4927.
13. Kima H, Himenob T, Kokuboc T, et al. 2005; Process and kinetics of bonelike apatite formation on sintered hydroxyapatite in a simulated body fluid. Biomaterials 26: 4366-4373.
14. Langer R, Vacanti JP. 1993; Tissue Engineering. Science 260: 920-926.
15. Leach JK, Kaigler D, Wang Z, et al. 2006; Coating of VEGF-releasing scaffolds with bioactive glass for angiogenesis and bone regeneration. Biomaterials 27: 3249-3255.
16. Marzouk KM, Gamal AY, Al-Awady AA, et al. 2007; Osteoconductive effects of vinyl styrene microbeads in rat calvarial defects. J Oral Maxillofac Surg 65: 1508-1516.
17. McClung MR, Geusens P, Miller PD, et al. 2001; Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344: 333-340.
18. Meinel L, Fajardo R, Hofmann S, et al. 2005; Silk implants for the healing of critical size bone defects. Bone 37: 688-698.
19. Reinholz GG, Getz B, Pederson L, et al. 2000; Bisphosphonates Directly Regulate Cell Proliferation, Differentiation, and Gene Expression in Human Osteoblasts. Cancer Res 60: 6001-6007.
20. Reszka AA, Halasy-Nagy JM, Masarachia PJ, et al. 1999; Bisphosphonates act directly on the osteoclast to induce caspase cleavage of Mst1 kinase during apoptosis. J Biol Chem 274: 34967-34973.
21. Rogers MJ. 2003; New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des, 9: 2643-2658.
22. Russell RGG and Rogers MJ. 1999; Bisphosphonates: From the laboratory to the clinic and back again, Bone 25: 97-106.
23. Sawyer AA, Song SJ, Susanto E, et al. 2009; The stimulation of healing within a rat calvarial defect by mPCL-TCP/collagen scaffolds loaded with rhBMP-2. Biomaterials 30: 2479-2488.
24. Schliephake H, Weich HA, Dullin C, et al. 2008; Mandibular bone repair by implantation of rhBMP-2 in a slow release carrier of polylactic acid-An experimental study in rats. Biomaterials 29: 103-110.
25. Schmitz JP, Hollinger JO. 1986; The critical size defect as an experimental model for craniomandibulofacial nonunions. Clin Orthop Relat Res 205: 299-308.
26. Shin M, Yoshimoto H, Vacanti JP. 2004; In vivo bone tissue engineering using mesenchymal stem cells on a novel electrospun nanofibrous scaffold. Tissue Eng 10: 33-41.
27. Urist MR. 1965; Bone: formation by autoinduction. Science 150: 893-899.
28. Vaananen HK, Zhao H, Mulari M, et al. 2000; The cell biology of osteoclast function. J Cell Sci 113: 377-381.
29. Williams JM, Adewunmi A, Schek RM, et al. 2005; Bone tissue engineering using polycaprolactone scaffolds fabricated via selective laser sintering. Biomaterials 26: 4817-4827.
30. Zakikhani M. 1999; United States Patent 5980776.